Immunovant Sciences GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Basel Switzerland (2018)

Organization Overview

First Clinical Trial
2019
NCT03922321
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Immunovant Sciences GmbH

Active Ingredients

Drugs in Phase 3 Trials (1)

hbm9161 (6 trials)

Drugs in Phase 2 Trials (1)

rvt-1401 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Hemolytic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Eye Diseases (Phase 2)

Graves Ophthalmopathy (Phase 2)

Hemolysis (Phase 2)

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 2